TY - JOUR AU - Farooqi, Rukhsana Javed AU - Farooqi, Javed Iqbal PY - 2011/07/25 Y2 - 2024/03/29 TI - EFFICACYAND SAFETY OF INTERFERON ALPHA 2 B PLUS RIBAVIRIN COMBINATION IN CHRONIC HEPATITIS C PATIENTS WITH PULMONARY TUBERCULOSIS JF - Journal of Postgraduate Medical Institute JA - J Postgrad Med Inst VL - 19 IS - 2 SE - Original Article DO - UR - https://jpmi.org.pk/index.php/jpmi/article/view/32 SP - AB - <span style="font-family: Times New Roman; color: #1f1a17; font-size: x-small;"><span style="font-family: Times New Roman; color: #1f1a17; font-size: x-small;"><span style="font-family: Times New Roman; color: #1f1a17; font-size: x-small;"><p>Objective: To assess the efficacy of combination therapy of interferon alpha-2b plus Ribavirin in patients</p><p>of chronic hepatitis C and pulmonary TB</p><p>Material and Methods: This retrospective study comprised of personal series of patients in</p><p>Gastroenterology Unit, HMC Peshawar and Saidu Group of Teaching Hospitals Swat, from June 1999 to</p><p>December 2002. Records of chronic hepatitis C and pulmonary TB, were analyzed for base-line</p><p>parameters, response rates, and any adverse effects. Standard anti-TB was given uninterrupted along with</p><p>close monitoring of all the patients.</p><p>Results: This study was conducted on 22 males and 11 females (33 patients) with chronic hepatitis C and</p><p>pulmonary tuberculosis.</p></span></span></span><span style="font-family: Times New Roman; color: #1f1a17; font-size: x-small;"><span style="font-family: Times New Roman; color: #1f1a17; font-size: x-small;"><span style="font-family: Times New Roman; color: #1f1a17; font-size: x-small;"><span style="font-family: Times New Roman; color: #1f1a17; font-size: x-small;"><p>End-treatment response:</p></span></span></span><p> </p></span><p><span style="font-family: Times New Roman; color: #1f1a17; font-size: x-small;"></span><p> </p><span style="font-family: Times New Roman; color: #1f1a17; font-size: x-small;"><span style="font-family: Times New Roman; color: #1f1a17; font-size: x-small;"><span style="font-family: Times New Roman; color: #1f1a17; font-size: x-small;"><span style="font-family: Times New Roman; color: #1f1a17; font-size: x-small;"><p>Sustained viral response:</p></span></span></span><p> </p></span><p><span style="font-family: Times New Roman; color: #1f1a17; font-size: x-small;"></span><p> </p></p><p><span style="font-family: Times New Roman; color: #1f1a17; font-size: x-small;"></span><p> </p></p><p><span style="font-family: Times New Roman; color: #1f1a17; font-size: x-small;">Serum ALT levels remained normal and HCV-RNA PCR remained undetectable</span><p> </p></p><p>at the end of 6 months follow-up period in 15 out of 22 male patients (68.18%), as compared to 8 out of</p><p>11 female patients (72.72%), (P &gt; 0.05).</p><p>Conclusion: We conclude that Interferon plus Ribavirin combination therapy is an effective and safe</p><p>therapy in the treatment of chronic hepatitis C patients having pulmonary TB.</p></p><p><span style="font-family: Times New Roman; color: #1f1a17; font-size: x-small;"></span><p> </p></p><p><span style="font-family: Times New Roman; color: #1f1a17; font-size: x-small;">serum ALT levels became normal in 18 out of 22 male patients (81.81%), as</span><p> </p></p><p>compared to 10 out of 11 female patients (90.90%), (P &gt; 0.05). Serum HCV-RNA became negative in 17</p><p>out of 22 male patients (77.27%), as compared to 9 out of 11 female patients (81.81%), (P &gt; 0.05).</p> ER -